Vivoryon Therapeutics: Promising Results Against Diabetic Kidney Disease
Vivoryon Therapeutics presented new data analyses at the World Congress of Nephrology, reinforcing the scientific validation of its therapeutic approach based on the inhibition of glutaminyl cyclase for the treatment of diabetic kidney diseases.
Consistent Outcomes from Phase 2 Studies
Vivoryon analyzed renal function data from two independent phase 2 studies, VIVIAD and VIVA-MIND, showing highly consistent results between the two studies. The new analyses presented at the World Congress of Nephrology confirm that the effect of varoglutamstat on eGFR (estimated glomerular filtration rate) was more significant in older participants with diabetes than in older participants without diabetes. In diabetic participants with a lower baseline eGFR, the magnitude of the effect was comparable or greater than that observed in the total population of diabetic participants. Data from a murine model of diabetic kidney disease also showed significant improvements in inflammation, glomerulosclerosis, and renal function.
Validating the Inhibition Approach
These results strengthen the validity of the approach of inhibiting glutaminyl cyclase to address the underlying inflammatory and fibrotic changes in diabetic kidney disease. Vivoryon is continuing the development of varoglutamstat, its flagship first-in-class QPCT/L inhibitor that can be administered orally, in patient populations with diabetes and more advanced stages of chronic kidney disease.
